Clinical Trial Update: An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC [Phase 2, Phase 3]

View source ↗

Summary

An open-label Phase II/III randomized trial comparing PFLL versus GP combined with JS001 as first-line therapy for metastatic nasopharyngeal carcinoma; trial no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• GP (gemcitabine and cisplatin)
• JS001 (PD-1 inhibitor)
• PFLL

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasopharyngeal Carcinoma, Metastasis | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING